Fort Point Capital Partners’s Ionis Pharmaceuticals IONS Stock Holding History

Fort Point Capital Partners’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-6,804	Closed	-$368K	–	129
2018 Q4	$368K	Hold	6,804	–	–	0.15%	90
2018 Q3	$351K	Buy	+6,804	New	+$320K	0.11%	105
2018 Q2	–	Sell	-6,849	Closed	-$302K	–	141
2018 Q1	$302K	Buy	+6,849	New	+$348K	0.11%	116
2017 Q4	–	Sell	-7,804	Closed	-$396K	–	148
2017 Q3	$396K	Buy	+7,804	New	+$409K	0.19%	87

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fort Point Capital Partners's IONS Position: Q1 2019 in Review

Fort Point Capital Partners sold out of Ionis Pharmaceuticals (IONS) in Q1 2019, closing a stake of 6,804 shares — an estimated $368K sold.

Fort Point Capital Partners first reported a position in IONS in Q3 2017 and held it in 4 quarters. The position peaked at $396K in Q3 2017. 392 funds tracked by Wall St. Rank hold IONS as of Q1 2019.

Fort Point Capital Partners reported no remaining Ionis Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
Fort Point Capital Partners sold 6,804 Ionis Pharmaceuticals shares in Q1 2019, an estimated $368K.
Fort Point Capital Partners first reported a position in Ionis Pharmaceuticals in Q3 2017 and held it in 4 quarters.
Fort Point Capital Partners's Ionis Pharmaceuticals position peaked at $396K in Q3 2017.
392 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2019.

Based on Fort Point Capital Partners's 13F filing for Q1 2019, filed 13 May 2019.